| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPPI | Common Stock, $0.001 par value | Award | $0 | +335K | +1142.56% | $0.00 | 364K | Jun 21, 2022 | Direct | F1 |
| transaction | SPPI | Common Stock, $0.001 par value | Sale | -$2.8K | -3.57K | -0.98% | $0.79 | 360K | Jun 21, 2022 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SPPI | Stock Option (Right to Buy) | Award | $0 | +1.52M | $0.00 | 1.52M | Jun 21, 2022 | Common Stock | 1.52M | $0.71 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc's ("Spectrum") board of directors on May 25, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022. |
| F2 | All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer. |
| F3 | The option grant was approved by Spectrum's board of directors on May 25, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022. |
| F4 | One third of the aggregate amount of option shares shall vest on each of May 25, 2023, 2024 and 2025, respectively. |